-
EP2145624
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2145624
| EP2145624 - Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 29.07.2011 Database last updated on 24.08.2024 | Most recent event Tooltip | 29.07.2011 | Application deemed to be withdrawn | published on 31.08.2011 [2011/35] | Applicant(s) | For all designated states SANOFI 174, Avenue de France 75013 Paris / FR | [2011/30] |
| Former [2010/03] | For all designated states Sanofi-Aventis 174 Avenue de France 75013 Paris / FR | Inventor(s) | 01 /
Cariou, Roger c/o sanofi-aventis 174 avenue de France 75013 Paris / FR | 02 /
Chew, Paul c/o sanofi-aventis D303A route 202-206 08807-0800 Bridgewater / US | 03 /
Destors, Jean-Michel c/o sanofi-aventis 174 avenue de France 75013 Paris / FR | 04 /
Pillion, Gérard c/o sanofi-aventis 174 avenue de France 75013 Paris / FR | 05 /
Silvestre, Louise c/o sanofi-aventis 174 avenue de France 75013 Paris / FR | [2010/03] | Representative(s) | Romanowski, Caroline, et al Sanofi Département Brevets 54, rue La Boétie 75008 Paris / FR | [N/P] |
| Former [2010/03] | Romanowski, Caroline, et al Sanofi-Aventis 174 avenue de France 75013 Paris / FR | Application number, filing date | 08290704.9 | 18.07.2008 | [2010/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2145624 | Date: | 20.01.2010 | Language: | EN | [2010/03] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 09.12.2008 | Classification | IPC: | A61K31/7056, A61P7/02 | [2010/03] | CPC: |
A61K31/7056 (EP);
A61P7/02 (EP)
| Designated contracting states | FR [2010/38] |
| Former [2010/03] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR | Title | German: | Verwendung von Idrabiotaparinux zur Senkung der Blutungsinzidenz bei einer Thrombosebehandlung | [2010/03] | English: | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment | [2010/03] | French: | Utilisation d'idrabiotaparinux pour diminuer l'incidence de saignements au cours d'un traitement antithrombotique | [2010/03] | Examination procedure | 20.07.2010 | Examination requested [2010/35] | 21.07.2010 | Loss of particular rights, legal effect: designated state(s) | 27.09.2010 | Despatch of communication of loss of particular rights: designated state(s) AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR | 14.10.2010 | Despatch of a communication from the examining division (Time limit: M04) | 25.02.2011 | Application deemed to be withdrawn, date of legal effect [2011/35] | 05.04.2011 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2011/35] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 14.10.2010 | Fees paid | Renewal fee | 14.07.2010 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [DX]WO0224754 (SANOFI SYNTHELABO [FR], et al) [DX] 1-8 * page 1, line 4 - line 23; example 5 * * page 15, line 34 - page 16, line 19 * * page 16, line 24 - line 27 * * page 15, line 11 - line 28; claim 15 *; | [A]WO2007042469 (ORGANON NV [NL], et al) [A] 1-8 * abstract * * compounds 10, 17 * * page 42, line 11 - page 44, line 14; claim 24; tables 6,7 *; | [DA]WO2006030104 (SANOFI AVENTIS [FR], et al) [DA] 1-8 * page 2, line 20 - line 31 * * examples 1,2; claims 1-5,8,9 *; | [X] - HIRSH J ET AL, "Beyond unfractionated heparin and warfarin: Current and future advances", CIRCULATION 200707 US, (200707), vol. 116, no. 5, ISSN 0009-7322, pages 552 - 560, XP002503605 [X] 1-8 * page 555, column L, paragraph 2; table 1 * DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.106.685974 | [X] - ANONYMOUS, "Bioequipotency Study of SSR126517E and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs (EQUINOX)", (20080410), pages 1 - 4, URL: http://www.clinicaltrials.gov/ct2/show/NCT00311090?term=equinox&rank=1, (20081111), XP002503606 [X] 1-8 * page 1, line 1 - line L * | [X] - PRANDONI PAOLO ET AL, "Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.", EXPERT OPINION ON INVESTIGATIONAL DRUGS MAY 2008, (200805), vol. 17, no. 5, ISSN 1744-7658, pages 773 - 777, XP008098574 [X] 1-8 * abstract * * page 776, column R, paragraph 2 - paragraph 4 * DOI: http://dx.doi.org/10.1517/13543780802016209 | [T] - SAVI P ET AL, "Reversible biotinylated oligosaccharides: A new approach for a better management of anticoagulant therapy", JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2008 GB, (2008), vol. 6, no. 10, ISSN 1538-7933 1538-7836, pages 1697 - 1706, XP002503607 [T] 1-8 * the whole document * DOI: http://dx.doi.org/10.1111/J.1538-7836.2008.03089.X | by applicant | WO0224754 | - H.R. BULLER, CHEST, (2004), vol. 126, no. 3, pages 401S - 428S | - D.J. QUINLAN ET AL., ANN. INTERN. MED., (2004), vol. 140, pages 175 - 83 | - J. ANSELL ET AL., CHEST, (2008), vol. 133, pages 160S - 198S | - N. ENGL. J. MED., (2007), vol. 357, no. 11, pages 1105 - 1112 | - N. ENGL. J. MED., (2007), vol. 357, pages 1094 - 104 | - JOURNAL OF AMERICAN MEDICAL ASSOCIATION (JAMA, (2005), vol. 293, no. 6, pages 681 - 689 |